Benefit of Adjuvant Traditional Herbal Medicine With Chemotherapy for Resectable Gastric Cancer

• Published in: Integrative Cancer Therapies Vol. 17; no. 3; pp. 619 - 627
• Main Authors: Lee, Yu Kyung, Bae, Kyeore, Yoo, Hwa-Seung, Cho, Seung-Hun
• Format: Book Review Journal Article
• Language: English
• Published: Los Angeles, CA SAGE Publications 01.09.2018; SAGE PUBLICATIONS, INC; SAGE Publishing
• Subjects: Animals; Antineoplastic Agents - therapeutic use; Antineoplastic Agents, Phytogenic - therapeutic use; Chemotherapy; Chemotherapy, Adjuvant - methods; Clinical trials; Confidence intervals; Disease-Free Survival; Gastric cancer; Herbal medicine; Herbal Medicine - methods; Humans; Medicine, Traditional - methods; Meta-analysis; Review; Statistical analysis; Stomach Neoplasms - drug therapy; Stomach Neoplasms - mortality; Survival; Survival Rate; meta-analysis; gastric cancer; randomized controlled trials; systematic review; traditional herbal medicine
• DOI: 10.1177/1534735417753542
• ISSN: 1534-7354

Introduction: Stomach cancer, historically, has a low survival rate advances in curative resection procedures. Objectives: To assess the potential benefits of traditional herbal medicines in conjunction with chemotherapy in postoperative gastric cancer patients in terms of overall survival and disease-free survival. Data Sources: We searched the Cochrane Central Register of Controlled Trials, MEDLINE, EMBASE, a Chinese database (CNKI), a Korean database, a Japanese database, AMED, and CINAHL up to September 2016. We summarized survival data from all RCTs. Study Selection: All RCTs of oral traditional medicines for resectable gastric cancer compared with chemotherapy alone were eligible. Data Extraction: Thirteen eligible trials with survival data (1075 patients) were deemed eligible for inclusion. Results: There were 217 documented deaths of the 574 patients assigned to adjuvant traditional medicines groups and 319 documented deaths of the 501 patients assigned to the chemotherapy-only groups. Adjuvant traditional medicines were associated with a statistically significant benefit in terms of overall survival rate (hazard ratio = 0.56; 95% confidence interval = 0.47-0.66; P < .00001) and disease-free survival (hazard ratio = 0.54; 95% confidence interval = 0.43-0.66; P < .00001). Conclusion: Among the RCTs included, the inclusion of postoperative adjuvant traditional medicines was associated with reduced risk of death in gastric cancer patients, when survival rates were compared with the group of patients who received chemotherapy alone. However, most of the included studies utilized are thought to be of low quality, so it would certainly appear that more trials are both advisable and necessary to arrive at correct and convincing conclusions.